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analysis  after  resection  of  2  hepatocellular  adenomas  (HCAs)  (20  and  2  cm)  in  a  53-year-old
female patient  were  performed.  On  imaging,  the  large  lesion  resembled  a  myxoid  HCA,  while
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the  small  lesion  resembled  a  more  conventional  HCA  with  a  small  myxoid/fluid  area.  On  micro-
scopy, the  large  lesion  showed  cords  and  nests  of  hepatocytes  embedded  in  abundant  myxoid
matrix, while  the  small  lesion  resembled  a  conventional  HCA  with  small  foci  of  myxoid  change
and serosities;  both  consistent  with  a  myxoid  HCA.  Immunophenotyping  and  molecular  sub-
typing excluded  inflammatory  HCA,  CTNNB1  mutated  HCA  and  sonic  hedgehog  HCA,  and  was
consistent with  HNF1A  mutated  HCA.  The  myxoid  change  as  well  as  the  serosities  may  allow
imaging diagnosis  of  myxoid  HCA.  As  fluid  vacuoles  can  also  be  present  in  ASS1  +  HCA,  sonic
hedgehog  HCA  has  to  be  considered  in  the  differential  diagnosis.
© 2020  Les  Auteurs.  Publie´  par  Elsevier  Masson  SAS.  Cet  article  est  publie´  en  Open  Access  sous
licence CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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olecular  classification  divided  hepatocellular  adenoma
HCA)  into  different  subtypes,  based  on  inactivating  muta-
ions  in  hepatocyte  nuclear  factor  1A  (HNF1A),  activations  of
nflammatory  signalling  pathways,  activating  mutations  in  ß-
atenin  (CTNNB1)  or  activation  of  sonic  hedgehog  pathway
1,2].  Myxoid  HCA  is  a  rare  HCA  variant,  characterised  by
he  presence  of  prominent  myxoid  stroma  [3—5]. It  remains
ontroversial  whether  it  is  specific  for  a  known  HCA  subtype
4—6].  Sonic  hedgehog  HCA  (shHCA)  is  a  recently  described
ew  subtype  of  HCA  with  genomic  fusion  between  inhibin
eta  E  subunit  (INHBE)  and  GLI  family  zinc  finger  1  (GLI1),
eading  to  overexpression  of  GLI1,  a  transcription  factor
ontrolling  sonic  hedgehog  pathway  activation  [1].  Prosta-
landin  D  synthase  (PTGDS)/argininosuccinate  synthase  1
ASS1)  overexpression  by  immunohistochemistry  was  sug-
ested  to  be  a  reliable  surrogate  marker  of  shHCA  [1,7—9].
hese  lesions  have  a  high  risk  of  bleeding  [1,7].  There  are  no
ypical  features  allowing  accurate  non-invasive  diagnosis  of
hHCA  on  imaging.  ASS1  positive  HCA  (ASS1  +  HCA)  is  a  sub-
ype  of  HCA,  similar  if  not  identical  to  shHCA  [8].  ASS1  +  HCA
hows  fluid  vacuoles  and  serosities,  leading  to  the  presence
f  peculiar  fluid  vacuoles  on  imaging  [8,10].
We  report  a  patient  with  two  myxoid  HCAs.  Imaging
eatures,  histological  characteristics,  immunohistochemical
rofile  and  molecular  analysis  are  described.
This  study  was  approved  by  the  Medical  Ethics  Committee
f  Ghent  University  Hospital,  and  written  informed  consent
as  obtained  from  the  patient.
aterial and methods
istopathology  and  Immunohistochemistry
he  specimen  was  routinely  processed  for  light  microscopy.
n  selected  blocks  picrosirius  red,  reticulin  and  Alcian  blue
taining  (pH  2.5)  was  performed  per  lab  protocol.  Mas-
on’s  trichrome,  Periodic  Acid-Schiff  (PAS),  PAS  with  diastasePour  citer  cet  article  :  De  Vos  N,  et  al.  Myxoid  hepatocellular  
distinct  imaging  features:  A  case  report  with  immunohistochem
Hepatol  Gastroenterol  (2020),  https://doi.org/10.1016/j.clinr
nd  Perls  staining  was  performed  on  the  BenchMark  Spe-
ial  Stains  platform  (Ventana;  Roche,  Tuscon,  AZ).  A  panel
f  antigens  was  applied  to  selected  paraffin  blocks  using
n  automated  immunostainer  (BenchMark  XT  Ventana)  with
d
t
f
mppropriate  controls.  The  panel  of  immunohistochemical
tains  included  HepPar1  (OCH1E5,  Agilent,  Santa  Clara,  CA,
/600),  arginase-1  (ABS535,  Merck  KGaA,  Darmstadt,  Ger-
any,  1/3000),  CK7  (SP52,  Ventana,  RTU),  GS  (glutamine
ynthetase,  Clone  6,  BD  Transduction  Laboratories,  BD  Bios-
iences,  San  Jose,  CA,  1/1500),  -catenin  (Beta-catenin,
lone  14,  Ventana,  RTU),  LFABP  (liver  fatty  acid  binding
rotein,  L2B10,  Abcam,  Cambridge,  UK,  1/800),  CRP  (C-
eactive  protein,  Y284,  Abcam,  1/800),  SAA  (serum  amyloid
,  mc1,  Agilent,  Santa  Clara,  CA,  1/1000),  ASS1  (arginino-
uccinate  synthase  1,  HPA020896,  Sigma-Aldrich,  St.  Louis,
O,  1/1000),  PTGDS  (prostaglandin  D  synthase,  HPA004938,
igma-Aldrich,  St.  Louis,  MO,  1/25),  glypican  3  (GC33,  Ven-
ana,  RTU),  HSP  70  (heat  shock  protein  70,  W27,  Santa
ruz  Biotechnology,  Santa  Cruz,  CA,  1/100),  and  alpha-
etoprotein  (polyclonal,  Agilent,  1/200).
ase presentation
 53-year-old  woman  presented  with  a  large  liver  mass,  an
ncidental  finding  on  CT  after  trauma.  It  was  located  in  the
eft  liver  lobe  and  had  a  maximal  diameter  of  20  cm.  In  addi-
ion,  a  smaller  lesion  was  observed  in  liver  segment  VI.  She
ad  no  significant  past  medical  history.  She  had  taken  oral
ontraceptives  for  many  years.
On  MRI  (Fig.  1),  the  large  lesion  in  the  left  liver
obe  was  markedly  hyperintense  with  interspersed  bands
f  lower  signal  intensity  on  T2-weighted  imaging  (T2-WI).
n  T1-weighted  imaging  (T1-WI),  the  lesion  was  mar-
edly  hypointense.  After  intravenous  administration  of  the
epatocyte-specific  gadolinium  contrast  agent  gadobenic
cid  (Gd-BOPTA),  the  lesion  demonstrated  heterogeneous,
entripetal-predominant  arterial  enhancement  and  progres-
ive  and  more  homogeneous  enhancement  during  later
hases.  During  hepatobiliary  phase  imaging,  the  lesion  sho-
ed  no  contrast  retention,  indicating  absence  of  normally
unctioning  hepatocytes  and/or  bile  ducts.  These  findings
re  compatible  with  a  myxoid  hepatocellular  neoplasm.
t  may  be  difficult  to  distinguish  this  lesion  from  a  giant
avernous  hemangioma.  However,  the  classic  peripheraladenoma,  a  rare  variant  of  hepatocellular  adenoma  with
ical  and  molecular  analysis  and  literature  review.  Clin  Res
e.2020.06.004
iscontinuous  globular  enhancement  with  progressive  cen-
ripetal  filling  in  giant  cavernous  hemangioma  is  different
rom  the  more  heterogeneous  and  progressive  enhance-
ent  seen  in  a  myxoid  hepatic  neoplasm  [5].  The  small
Pour  citer  cet  article  :  De  Vos  N,  et  al.  Myxoid  hepatocellular  
distinct  imaging  features:  A  case  report  with  immunohistochem
Hepatol  Gastroenterol  (2020),  https://doi.org/10.1016/j.clinr
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Figure  1  Axial  MRI  confirms  both  lesions.  A.  On  T2-weighted  imaging,  the  left-sided  lesion  demonstrates  marked  hyperinten-
sity with  interspersed  bands  of  lower  signal  intensity,  while  the  right-sided  lesion  is  discretely  hyperintense  to  the  adjacent  liver
parenchyma, with  a  central  punctiform  area  of  marked  hyperintensity.  B.  On  T1-weighted  imaging,  the  left-sided  lesion  is  markedly
hypointense, while  the  right-sided  lesion  is  discretely  hypointense  to  the  surrounding  liver  parenchyma,  with  a  central  punctiform
area of  marked  hypointensity.  C—E.  Arterial,  portal  venous  and  delayed  phase  dynamic  contrast-enhanced  fat-saturated  T1-weighted
images with  gadobenic  acid  (Gd-BOPTA)  demonstrate  heterogeneous,  centripetal-predominant  arterial  enhancement  that  progres-
sively and  more  homogeneously  enhances  on  later  phases  in  the  left-sided  lesion.  The  right-sided  lesion  remains  hypointense  to
normal liver  parenchyma  in  all  phase,  with  progressive  enhanceme
phase image  demonstrates  absence  of  contrast  retention  within  the  l
and/or bile  ducts.
Figure  2  Left  lobectomy  specimen.  A.  A  whitish  red  large
liver mass  is  visible  through  the  liver  capsule.  B.  On  cutting
a liver  mass  with  a  diameter  of  20  cm  is  observed,  displaying
cystic sticky  mucoid  areas,  alternating  with  small  fibrotic  and
hemorrhagic  areas.
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Tnt  of  the  central  punctiform  area.  F.  90-minute  hepatobiliary
esions,  indicating  absence  of  normally  functioning  hepatocytes
esion  in  the  right  liver  lobe  was  discretely  hyperintense
o  the  adjacent  liver  parenchyma  on  T2-WI,  with  a  central
unctiform  area  of  marked  hyperintensity.  On  T1-WI,  the
esion  was  discretely  hypointense,  with  a  central  area  of
arked  hypointensity.  After  administration  of  Gd-BOPTA,
he  lesion  enhanced  slightly  less  than  normal  liver  paren-
hyma  in  all  phases,  except  for  the  central  punctiform
rea,  which  showed  progressive  enhancement.  During  hepa-
obiliary  phase  imaging,  the  lesion  showed  no  contrast
etention.  These  findings  are  compatible  with  a  hepatocellu-
ar  adenoma  with  a  central  punctiform  myxoid  component.
his  lesion  may  be  difficult  to  distinguish  from  focal  nodular
yperplasia  (FNH)  with  a  central  scar.  The  lack  of  contrast
etention  during  hepatobiliary  phase  imaging,  however,  is
typical  for  FNH  [5].
Hand-assisted  laparoscopic  left  lobectomy  was  perfor-
ed,  in  combination  with  resection  of  the  lesion  in  segment
I.  Grossly,  a  whitish  red  large  liver  mass  of  20  cm  dia-
eter  was  observed  through  the  liver  capsule  in  the  left
obectomy  specimen  (Fig.  2A).  It  was  sharply  delineated  and
howed  cystic  sticky  mucoid  areas  alternating  with  hemor-
hagic  areas  (Fig.  2B).  The  resection  of  segment  VI  contained
n  irregularly  delineated  mass  of  2  cm  diameter,  slightly
aler  in  colour  than  the  surrounding  parenchyma.  Microsco-
ically,  the  large  tumour  predominantly  consisted  of  cords
nd  small  clusters  of  monotonous  bland  appearing  polygonal
ells  with  vesicular  nuclei  with  small  nucleoli,  embedded
n  an  abundant  myxoid/mucoid  matrix  (Fig.  3A).  The  cyto-
lasm  of  the  tumour  cells  was  granular  eosinophilic  andadenoma,  a  rare  variant  of  hepatocellular  adenoma  with
ical  and  molecular  analysis  and  literature  review.  Clin  Res
e.2020.06.004
ontained  abundant  lipofuscin  granules  (Fig.  3B).  Hemorrha-
ic  areas  were  present,  as  well  as  few  fibrous  septa  (Fig.  3C).
he  myxoid/mucoid  matrix  was  lightly  Alcian  blue  positive
Pour  citer  cet  article  :  De  Vos  N,  et  al.  Myxoid  hepatocellular  adenoma,  a  rare  variant  of  hepatocellular  adenoma  with
distinct  imaging  features:  A  case  report  with  immunohistochemical  and  molecular  analysis  and  literature  review.  Clin  Res
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Figure  3  Histopathology  large  tumour.  A.  The  tumour  predominantly  consists  of  cords  and  small  clusters  of  cells  embedded  in  an
abundant myxoid/mucoid  matrix  (arrowheads)  with  at  the  periphery  of  the  tumour  solid  areas  of  neoplastic  cells;  arrows  indicate
the limits  between  HCA  and  non-tumoural  liver  (NT).  B.  Higher  magnification  of  the  area  marked  with  a  rectangle  in  A.  The  cytoplasm
of the  tumour  cells  is  granular  eosinophilic  and  contains  abundant  lipofuscin  granules  (inset).  C.  Hemorrhagic  areas  are  present.
D. The  myxoid/mucoid  matrix  is  lightly  Alcian  blue  positive.  E.  and  weakly  PAS  diastase  positive.
Figure  4  Histopathology  small  tumour.  A.  The  tumour  consists  of  normal  appearing  hepatocytes  arranged  in  cords,  with  small
foci of  myxoid/mucoid  stroma  and  serosities;  arrows  indicate  the  limits  between  HCA  and  non-tumoural  liver  (NT).  B.  Higher
magnification of  the  area  marked  with  a  rectangle  in  A  showing  small  foci  of  myxoid/mucoid  stroma  and  serosities.  C.  Foci  of
myxoid/mucoid  stroma  are  lightly  Alcian  blue  positive.
ARTICLE IN PRESSModele +CLINRE-1478; No. of Pages 9
Imaging  features,  immunohistochemical  and  molecular  analysis  of  myxoid  HCA  xxx.e5
Figure  5  LFABP  staining  large  tumour.  The  tumour  (HCA)  shows  a  peripheral  narrow  rim  of  cells  with  weak  LFABP  staining  in
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becoming completely  negative;  arrows  indicate  the  limits  betw
(Fig.  3D)  and  weakly  PAS  diastase  positive  (Fig.  3E).  No  intra-
cellular  mucin  was  observed.  Focally,  predominantly  at  the
periphery  of  the  lesion,  solid  nests  of  neoplastic  cells  resem-
bling  normal  hepatocytes  were  observed,  surrounding  large,
predominantly  thin-walled  vessels.  The  lesion  in  addition
contained  numerous  small  unpaired  arteries.  The  smaller
lesion  consisted  of  normal  appearing  hepatocytes  arran-
ged  in  cords,  with  focal  sinusoidal  dilatation  and  peliosis,
and  small  foci  of  similar  appearing  myxoid/mucoid  stroma
and  serosities  (Fig.  4A—C).  In  this  lesion  too,  hepatocytes
contained  numerous  lipofuscin  granules.  Both  lesions  lacked
portal  tracts  and  showed  mild  steatosis.  The  surrounding
non-tumoural  liver  parenchyma  appeared  unremarkable.  In
both  lesions,  the  tumour  cells  were  positive  for  HepPar1
and  arginase-1.  Few  tumour  cells  were  CK7  positive,  but
there  was  no  positivity  for  CK19.  Both  tumours  displayed  a
peripheral  narrow  rim  of  cells  with  weak  LFABP  (liver  fatty
acid  binding  protein)  staining,  gradually  diminishing  towards
the  centre  of  the  lesions  and  becoming  completely  negativePour  citer  cet  article  :  De  Vos  N,  et  al.  Myxoid  hepatocellular  
distinct  imaging  features:  A  case  report  with  immunohistochem
Hepatol  Gastroenterol  (2020),  https://doi.org/10.1016/j.clinr
(Fig.  5),  whereas  LFABP  was  normally  expressed  in  the  sur-
rounding  liver  parenchyma.  The  tumours  were  negative  for
SAA  (serum  amyloid  A)  and  CRP  (C-reactive  protein).  There
was  no  increased  staining  for  GS  (glutamine  synthetase)  and
p
T
6
BT),  gradually  diminishing  towards  the  centre  of  the  lesion  and
CA  and  non-tumoural  liver  (NT).
o  nuclear  accumulation  of  -catenin.  PTGDS  (prostaglandin
 synthase)  staining  at  low  power  view  appeared  heteroge-
eous  due  to  myxoid  areas,  but  was  clearly  overexpressed
n  both  lesions,  compared  to  the  surrounding  liver  paren-
hyma.  At  higher  magnification,  the  labelling  was  however
oarsely  granular,  corresponding  to  strong  aspecific  stai-
ing  of  lipofuscin  granules,  but  not  a  diffuse  cytoplasmic
taining  (Fig.  6A—D).  ASS1  (argininosuccinate  synthase  1)
taining  showed  diffuse  expression  in  both  lesions,  contras-
ing  with  normal  expression  with  zonation  in  non-tumoural
iver.  Due  to  steatotic  areas,  the  staining  appeared  focally
eterogeneous  with  weakly  stained  areas  alternating  with
arker  stained  areas.  However,  at  low  magnification,  no
verall  higher  intensity  than  the  zonated  staining  in  the  non-
umoural  liver  was  observed  (Fig.  7A  and  B).  There  was  no
oss  of  reticulin  and  the  lesions  did  not  display  positivity
or  glypican  3,  HSP70  (heat  shock  protein  70)  or  alpha-
etoprotein.
Tumoural  DNA  was  extracted  from  formalin-fixed,adenoma,  a  rare  variant  of  hepatocellular  adenoma  with
ical  and  molecular  analysis  and  literature  review.  Clin  Res
e.2020.06.004
araffin-embedded  (FFPE)  sections  after  macrodissection.
argeted  next-generation  sequencing  was  performed  with  a
9  gene  panel  including  AKT1,  ALK,  APC,  AR,  BAP1,  BRAF,
RCA1,  BRCA2,  CCND1,  CDK4,  CDK6,  CDKN2A,  CDKN2B,
ARTICLE IN PRESSModele +CLINRE-1478; No. of Pages 9
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Figure  6  PTGDS  immunohistochemistry.  A.  The  large  tumour  (HCA)  shows  clear  overexpression  compared  to  the  surrounding  non-
tumoural liver  parenchyma  (NT);  arrows  indicate  the  limits  between  HCA  and  non-tumoural  liver  (NT).  B.  Higher  magnification  of
the area  marked  with  a  rectangle  with  full  line  in  A  showing  positive  tumour  cells.  C.  Higher  magnification  of  the  area  marked  with
a rectangle  with  dashed  line  in  A  showing  no  labelling  in  periportal  hepatocytes  and  lipofuscin  granules  in  centrilobular  hepatocytes
in non-tumoural  liver.  D.  Similar  staining  for  PTGDS  is  observed  in  the  smaller  lesion;  arrows  indicate  the  limits  between  HCA  and
non-tumoural liver  (NT).  Inset  shows  higher  magnification  of  the  area  indicated  with  an  asterisk:  Tumoural  cells  show  strong  coarsely
granular staining  suggestive  of  aspecific  labelling  of  lipofuchsin  granules,  which  are  much  more  abundant  in  the  tumour  compared
to the  non-tumoural  liver.
Figure  7  ASS1  immunohistochemistry.  A.  Large  lesion.  B.  Small  lesion.  Both  tumours  (HCA)  show  diffuse  expression,  without
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conation, but  there  is  no  overall  higher  intensity  than  the  zon
etween HCA  and  non-tumoural  liver  (NT).
TNNB1,  DDR2,  DICER1,  DPYD,  EGFR,  ERBB2,  ERBB3,  ERBB4,
SR1,  FBXW7,  FGFR1,  FGFR2,  FGFR3,  FOXL2,  FRK,  GATA3,
NA11,  GNAQ,  GNAS,  H3F3A,  H3F3B,  HIST1B3,  HIST1H3C,
NF1A,  HRAS,  IDH1,  IDH2,  IL6ST,  JAK1,  JAK2,  KIT,  KRAS,
AP2K1,  MET,  NRAS,  NTRK1,  NTRK3,  PDGFRA,  PIK3CA,
IK3R1,  POLE,  PTEN,  RB1,  RET,  RNF43,  ROS1,  SMAD4,
MARCA4,  SMARCB1,  SMO,  SPOP,  STAT3,  STK11,  TERT,  TP53
nd  VHL  (Roche,  Basel,  Switzerland).  This  panel  encom-Pour  citer  cet  article  :  De  Vos  N,  et  al.  Myxoid  hepatocellular  
distinct  imaging  features:  A  case  report  with  immunohistochem
Hepatol  Gastroenterol  (2020),  https://doi.org/10.1016/j.clinr
asses  genes  characteristic  for  beta-catenin  mutated  HCA
CTNNB1  exon  2,  3,  4,  7,  8/NM  001904.4/build  hg38),  for
nflammatory  HCA  (GNAS  exon  7,  8,  9/NM  000516.5/build
g38,  JAK1  exon  15,  16/NM  002227.4/build  hg38,
a
m
i
a staining  in  the  non-tumoural  liver;  arrows  indicate  the  limits
RK  exon  6/NM  002031.3/build  hg38,  STAT3  exon  3,
,  17,  20,  21/NM  139276.2/build  hg38,  IL6ST  exon
,  10/NM  002184.3/build  hg38),  for  HNF1A  mutated
CA  (HNF1A  all  exons/NM  000545.6/build  hg38)  and
or  malignant  transformation  in  HCA  (TERT  promoter
egion/NM  198253.2/build  hg38).  None  of  the  tumours
isplayed  a CTNNB1  mutation  in  exon  2,  3,  4,  7  or  8,
onsistent  with  the  absence  of  nuclear  ß-catenin  stainingadenoma,  a  rare  variant  of  hepatocellular  adenoma  with
ical  and  molecular  analysis  and  literature  review.  Clin  Res
e.2020.06.004
nd  absence  of  overexpression  of  GS  in  immunohistoche-
istry  [11].  In  addition,  no  TERT  mutation  was  detected
n  both  tumour  samples.  Molecular  analysis  did  not  reveal
rguments  for  inflammatory  HCA  as  no  activating  mutations
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were  observed  in  GNAS, JAK1, FRK, STAT3  or  IL6ST,
consistent  with  the  lack  of  overexpression  of  CRP  and  SAA
in  immunohistochemistry  [11].  In  the  large  lesion  (tumour
cell  percentage  80%),  a  variant  was  found  in  HNF1A  gene:
HNF1A  c.824  833del  p.(Glu275Glyfs*64)  at  36%  variant
allele  frequency  (VAF).  The  smaller  lesion  (tumour  cell  per-
centage  80%)  harboured  a  different  HNF1A  variant:  HNF1A
c.793T  >  G  [p.(Tyr265Asp)]  36%  VAF.  There  was  no  bi-allelic
variant  detected  in  HNF1A. In  addition,  in  both  lesions,
the  same  variant  was  found  in  Discoidin  Domain  Receptor
Tyrosine  Kinase  2  gene:  DDR2  c.861C  >  G  [p.(His287Gln)]
50%  VAF  and  49%  VAF,  respectively  in  the  large  lesion  and
in  the  smaller  lesion.  In  parallel,  copy  number  aberration
(CNA)  detection  by  copy  number  variation  sequencing
(CNV-seq)  was  performed  on  FFPE  tumour  tissue  [12].  This
showed  a  450  kb  duplication  in  chromosome  band  14q21.2
in  both  lesions.  This  region,  however,  does  not  contain
known  genes.  In  addition,  a  chromosome-5  duplication
could  be  detected  in  the  smallest  lesion  only.  However,
sample  quality  and  quantity  of  the  largest  lesion  was  lower,
resulting  in  a  higher  level  of  noise  in  the  copy  number
profile  and  hindering  identifying  CNAs.  Of  all  the  genes
actually  known  to  be  linked  to  hepatocellular  adenomas,
only  one,  IL6ST  linked  to  inflammatory  HCA,  is  localised  on
chromosome  5.  As  already  emphasised,  inflammatory  HCA
could  be  excluded  because  of  lack  of  overexpression  of  CRP
and  SAA  in  immunohistochemistry  [11].
Imaging,  histology  and  immunohistochemistry  of  both
liver  tumours  are  suggestive  of  HCAs  with  myxoid  com-
ponent.  The  large  lesion  in  the  left  liver  lobe  displayed
prominent  characteristics  of  myxoid  HCA  [3—6]. The  small
lesion  in  the  right  liver  lobe  resembled  more  conventio-
nal  type  HCA,  with  focal  prominent  sinusoidal  dilatation
and  peliosis;  however,  displaying  in  addition  small  foci  of
myxoid  change  and  serosities  [3—6].  The  serosities  obser-
ved  in  the  small  lesion  appear  identical  to  those  described
in  ASS1  +  HCA  [8,10].  There  was,  however,  no  overexpression
of  ASS1  compared  to  surrounding  non-tumoural  periportal
hepatocytes  and  only  aspecific  labelling  for  PTGDS,  making
the  diagnosis  of  shHCA  unlikely  [7].  Molecular  analysis  and
immunophenotyping,  with  mutation  of  HNF1A  and  dimini-
shed  LFABP  staining,  are  compatible  with  HNF1A  mutated
HCA  (HHCA).
The  patient  is  regularly  followed-up,  including  imaging,
and  is  without  evidence  of  local  disease  recurrence  or
metastases  24  months  following  surgery.
Discussion
Only  very  few  cases  of  myxoid  HCA  have  been  reported  in
the  literature  to  date  (Table  1).  Almost  all  cases  presented
with  multiple  adenomas,  and  the  myxoid  change  was  often
present,  at  least  focally,  in  multiple  adenomas  [3—5,13].
Myxoid  HCA  is  not  a  HCA  subtype,  but  a  variant,  probably
not  specific  to  one  of  the  HCA  subtypes.  It  is  described  in  the
latest  edition  of  the  WHO  Classification  of  Digestive  Tumours
under  the  chapter  of  HNF1A  inactivated  HCA  (HHCA)  as  aPour  citer  cet  article  :  De  Vos  N,  et  al.  Myxoid  hepatocellular  
distinct  imaging  features:  A  case  report  with  immunohistochem
Hepatol  Gastroenterol  (2020),  https://doi.org/10.1016/j.clinr
rare  feature  of  this  subtype  of  HCA.  In  all  cases  repor-
ted  in  the  literature  until  now,  where  immunophenotyping
and/or  molecular  subtyping  were  performed,  myxoid  adeno-
mas  were  characterised  by  loss  of  LFABP  expression  and/or
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NF1A  mutation  [4,6,13].  In  our  patient,  both  tumours  sho-
ed  weak  LFABP  expression  at  the  periphery  of  the  lesions,
radually  decreasing  towards  the  centre  and  becoming  com-
letely  negative.  This  staining  pattern  appears  different
rom  the  totally  absent  staining  that  is  usually  shown  in
NF1A  mutated  HCA  (HHCA)  and  is  also  not  mentioned  in
ther  myxoid  HCAs.  Decreased  LFABP  staining  in  HCA  has
een  previously  mentioned  in  some  shHCA,  a  subtype  of  HCA
ith  a  high  risk  of  severe  bleeding,  although  it  appears  to
e  diffuse  weak  labelling,  different  from  what  is  observed
n  the  present  case  [7—9]. In  both  tumours  of  our  patient,
 mono-allelic  variant  in  the  HNF1A  gene  was  observed.
imilarly,  Torbenson  et  al.  reported  heterozygous  mutations
n  HNF1A  in  the  myxoid  adenomas  from  the  Mayo  clinic
6]. Hypothetically,  mono-allelic  variants  might  be  a  pos-
ible  explanation  for  the  reduced  staining  for  LFABP  in  both
umours.  In  that  case,  we  would,  however,  expect  diffuse
educed  staining  and  the  hypothesis  of  a  relationship  with
educed  LFABP  staining  thus  remains  questionable.  Moreo-
er,  a  mono-allelic  variant  of  HNF1A  has  not  been  described
n  shHCA.  HNF1A  inactivation  in  HHCA  is  often  bi-allelic,
ut  mono-allelic  mutations  in  combination  with  LOH  have
lso  been  described.  LOH  can  remain  undetected  in  NGS
nd  CNVseq  analysis.  Peripheral  staining  of  the  tumours
ay  result  from  antigen  diffusion  from  the  surrounding  non-
umoural  liver  parenchyma,  leading  to  erroneous  conclusion
f  diminished  staining,  instead  of  loss  of  LFABP  expression.
ntigen  diffusion  is  a  possible  pitfall  in  immunohistochemis-
ry,  usually  resulting  from  delayed  fixation.
The  characteristic  prominent  myxoid  change  in  the  large
esion  allows  accurate  non-invasive  diagnosis  as  myxoid
epatocellular  neoplasm  on  imaging  [5].  The  myxoid  matrix
ight  be  the  result  of  degeneration  of  clotted  blood  in
eliotic  cysts  and  hemorrhagic  areas.  Moreover,  collagenous
ell-poor  zones  were  also  present,  as  well  as  some  dense
brotic  bands.  In  giant  cavernous  hemangiomas,  similar
reas  of  hypocellular  myxoid  tissue  can  be  observed,  thought
o  represent  an  intermediate  stage  in  the  evolution  from
hrombosis  within  the  vascular  channels  to  final  well-formed
brous  scars  [14]. The  frequent  presence  of  these  myxoid
ysts  in  giant  cell  hemangioma  may  contribute  to  the  misin-
erpretation  of  myxoid  HCA  with  prominent  myxoid  change
s  giant  cell  hemangioma  on  imaging  [15].  Also,  in  our  case,
he  large  lesion  in  the  left  liver  lobe  was  initially  considered
 giant  cavernous  hemangioma  on  MRI,  while  the  small  lesion
n  the  right  liver  lobe  was  thought  to  be  suggestive  of  a  HCA.
istologically,  distinction  of  myxoid  HCA  from  hemangioma
s  straightforward,  but  differentiation  from  mucin-producing
holangiocarcinoma  may  be  challenging.  Positivity  for  the
epatocyte  markers  HepPar1  and  arginase-1  and  negative
taining  for  the  cholangiocyte  maker  CK19  allow  to  avoid
isdiagnosis.
The  small  myxoid  HCA  in  our  patient  not  only  showed
mall  foci  of  myxoid  change,  but  also  fluid  vacuoles  and  sero-
ities  identical  to  those  reported  in  ASS1  +  HCA,  similar,  if
ot  identical,  to  shHCA  [10].  It  remains  unknown  why  these
uid  vacuoles  and  serosities,  which  are  very  frequent  in
SS1  +  HCA,  even  when  the  tumours  are  small,  lead  to  severeadenoma,  a  rare  variant  of  hepatocellular  adenoma  with
ical  and  molecular  analysis  and  literature  review.  Clin  Res
e.2020.06.004
leeding  in  shHCA,  while  they  appear  to  evolve  into  myxoid
oci  in  myxoid  HCA.  Both  tumours  in  our  patient  showed  a
utation  in  DDR2. As  DDR2  is  involved  in  remodelling  of  the
xtracellular  matrix,  it  might  be  implicated  in  development
ARTICLE IN PRESSModele +CLINRE-1478; No. of Pages 9
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Table  1  Characteristics  of  patients  with  myxoid  HCA  reported  in  the  literature,  including  the  present  case.
Number  of
tumours
Diameter  of
largest  tumour
M/F  Age  at
diagnosis
Miscellaneous
conditionsa
Malignant
transformation
Reference
1  16  cm  M  26  No  HCA  with  HCC  focusb Galassi  A  et  al.  [3]
6  4  cm M  34  No  HCA  Salaria  SN  et  al.  [4]
6  9  cm  M  45  No  HCA  Salaria  SN  et  al.  [4]
>  10  17.5  cm  M  20  No  HCA  Salaria  SN  et  al.  [4]
5  14.5  cm  F  65  No  HCA  Salaria  SN  et  al.  [4]
12  11.5  cm  M  45  No  HCA  Young  JT  et  al.  [5]
1  7  cm  M  52  Overweight
Hormone
replacement
therapy
HCA  with  subsequent
malignant
transformation
Young  JT  et  al.  [5]
1c 12  cm  F  52  Possible
Osler—Weber—Rendu
syndrome
Malignant
transformation
Putra  J  et  al.  [13]
>  10c 8.5  cm  M  27  Teralogy  of  Fallot  Malignant
transformation
Putra  J  et  al.  [13]
>  10  8  cm  F  53  No  Malignant
transformation
Putra  J  et  al.  [13]
>  10c 7  cm  F  55  Budd—Chiari
syndrome
Malignant
transformation
Putra  J  et  al.  [13]
1c 10  cm  F  64  No  Malignant
transformation
Putra  J  et  al.  [13]
2  20  cm  F  53  Oral  contraceptive
use
HCA  Present  case
a Oral contraceptive use, hormone replacement therapy or anabolic steroid use, diabetes, overweight, steatohepatitis or fibrosis of
non-tumoural liver, other underlying chronic liver disease.
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c Only focal myxoid change is reported (defined as < 50%). All ot
f  the  prominent  myxoid  stroma  [16].  This  also  remains
ypothetical,  as  DDR2  mutation  has  not  yet  been  investiga-
ed  in  other  myxoid  HCA.  The  fluid  vacuoles  and  serosities
ay,  in  addition  to  the  myxoid  change,  allow  imaging  diag-
osis  of  myxoid  HCA.  As  fluid  vacuoles  can  also  be  present
n  ASS1  +  HCA,  shHCA  has  to  be  considered  in  the  differen-
ial  diagnosis  [8,10].  This  case  emphasises  the  importance
f  correctly  interpreting  immunohistochemical  stainings  to
void  pitfalls  in  the  diagnosis  of  shHCA.  PTGDS/ASS1  ove-
expression  by  immunohistochemistry  was  suggested  to  be
 reliable  surrogate  marker  of  shHCA  [1,7—9].  Binding  of
TGDS  antibodies  to  lipofuscin  granules,  however,  can  be
isleading  and  should  not  be  confused  with  true  diffuse
ytoplasmic  PTGDS  staining.  Concerning  ASS1  immunohisto-
hemistry,  not  only  positivity,  but  overexpression  of  ASS1
n  the  tumour  in  comparison  to  the  non-tumoural  liver,  is
andatory  for  the  diagnosis  of  shHCA  [8].
Drawing  general  conclusions  based  on  the  few  reported
ases  in  literature  is  not  possible,  but  preliminary  observa-
ions  suggest  that  HCA  with  myxoid  features  is  more  common
n  males  and  is  less  related  to  obesity  and  diabetes  (Table  1)
1].  Seven  of  the  thirteen  reported  cases  of  myxoid  HCA
howed  malignant  transformation  (Table  1).  Five  cases  of
CA  with  myxoid  features  showing  malignant  transforma-Pour  citer  cet  article  :  De  Vos  N,  et  al.  Myxoid  hepatocellular  
distinct  imaging  features:  A  case  report  with  immunohistochem
Hepatol  Gastroenterol  (2020),  https://doi.org/10.1016/j.clinr
ion  were  HNF1A  mutated  adenomas  (in  2  of  these  cases,
nactivating  mutations  of  HNF1A  were  demonstrated,  while
lassification  in  the  3  other  cases  was  based  on  immuno-
istochemical  subtyping).  The  high  percentage  of  malignant
g
p
s
dases show in at least one lesion predominant myxoid features.
ransformation  in  the  reported  cases  of  myxoid  HCA,  howe-
er  not  necessary,  should  be  linked  to  inherent  molecular
haracteristics  of  the  lesion,  but  may  be  related  to  male
ender,  which  is  associated  with  a  higher  risk  for  malignant
ransformation  of  HCA  at  baseline,  independent  of  mole-
ular  classification.  Also,  the  large  tumour  size  might  be
mplicated  in  the  high  percentage  of  malignant  transfor-
ation.  As  differentiation  between  benign  and  malignant
yxoid  hepatocellular  neoplasms  is  not  possible  on  imaging,
hese  lesions  should  be  referred  for  surgery  [5].  In  addition,
ollow-up  after  surgery  is  required,  as  most  patients  with
yxoid  HCA  have  more  than  one  lesion  [4—6,16].
onclusions
mmunophenotyping  and  molecular  subtyping  of  two  myxoid
CAs  (20  and  2  cm)  excluded  inflammatory  HCA,  CTNNB1
utated  HCA  and  sonic  hedgehog  HCA  and  was  consistent
ith  HNF1A  mutated  HCA.  Remarkably,  next  to  small  myxoid
oci,  fluid  vacuoles  and  serosities  were  observed,  similar
o  the  fluid  vacuoles  resulting  from  degeneration  of  clot-
ed  blood  described  in  ASS1  +  HCA.  Development  of  new
echniques  for  molecular  subtyping,  including  detection  ofadenoma,  a  rare  variant  of  hepatocellular  adenoma  with
ical  and  molecular  analysis  and  literature  review.  Clin  Res
e.2020.06.004
enetic  fusions  and  small  chromosomal  deletions  as  well  as
roteomic  analysis  for  biomarker  quantification  on  FFPE  tis-
ue,  can  contribute  to  further  clarification  of  similarities  and
ifferences  between  myxoid  HCA  and  ASS1  +  HCA/shHCA  and
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Imaging  features,  immunohistochemical  and  molecular  anal
may  explain  why  these  fluid  vacuoles  and  serosities  lead  to
severe  bleeding  in  shHCA,  while  they  appear  to  evolve  into
myxoid  foci  in  myxoid  HCA.  The  myxoid  change  as  well  as
the  serosities  may  allow  imaging  diagnosis  of  myxoid  HCA.
As  fluid  vacuoles  can  also  be  present  in  ASS1  +  HCA,  shHCA
has  to  be  considered  in  the  differential  diagnosis.
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